Roche, Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China

Published: Apr 15, 2013

Roche Holding AG (ROG.VX) Mondat said it and Ascletis have entered into a collaboration to develop and commercialize Roche's investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). - It is estimated that more than 10 million patients in China are chronically infected with HCV. - The majority of these are genotype 1b, which has proven highly responsive to danoprevir. - Roche and Ascletis are joining forces to develop a therapy with the potential to address a serious public health problem and to provide an effective new treatment option for Chinese patients with HCV.

Back to news